Drugs / Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00793377 | ? → Sep 2001 | female breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00793377 ↗ |
| Route | Intravenous | “cyclophosphamide 600 mg/m2 (1 h i.v.)” NCT00793377 ↗ |